• Nippon Rinsho · Jul 2015

    [Vonoprazan: a novel potassium-competitive acid blocker].

    • Kentaro Sugano.
    • Nippon Rinsho. 2015 Jul 1; 73 (7): 1163-8.

    AbstractA potent, rapid acting potassium-competitive acid blocker, vonoprazan, is introduced for clinical use in Japan. A number of phase III clinical trials comparing the efficacy of vonoprazan with lansoprazole, showed non-inferior or superior effectiveness in a spectrum of acid-related diseases. In particular, vonoprazan was superior to regular dose of lansoprazole in healing severe gastroesophageal reflux diseases (Los Angeles grade C and D). A triple therapy regimen with vonoprazan, amoxicillin and clarithromycin for 7 days also showed an excellent eradication rate exceeding 90%. The adverse events across these trials were comparable with the standard dose of lansoprazole. As a consequence of profound acid suppression, serum gastrin during vonoprazan therapy rose to much higher levels than those during lansoprazole therapy, pointing to a requirement for the assurance of long-term safety of vonoprazan.

      Pubmed     Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…